Study of new radioactive treatments for GRPR-positive tumors
Part of Cancer, Digestive system, Kidney & urinary, Skin clinical trials.
This early-phase study tests two new radioactive treatments (lutetium-177 and actinium-225) together with a guided imaging agent in people with GRPR-positive solid tumors (including prostate, breast, or colorectal cancers). The goal is to see if these treatments can shrink tumors that have stopped responding to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer (prostate, breast, colorectal, or another GRPR-positive solid tumor) that has spread or is advanced.
- You have had a scan showing your tumor has a specific marker called GRPR.
- You have tried standard treatments and they didn't work, caused too many side effects, or aren't available for you.
- You are well enough to do most daily activities without help (performance status 0 or 1).
- You have at least one tumor that can be measured on scans (like a CT or MRI).
- You are at least 18 years old and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This early-stage trial tests a new experimental drug called HT547 that combines radioactive tracers to help doctors see and treat certain solid tumors (breast, head and neck, pancreatic, or brain cancer). The study will check if the drug is safe, how it moves through your body, and how much radiation it gives you.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.